Rhesus haemolytic disease is a condition where maternal antibodies cross the placenta and destroy fetal red blood cells, causing severe anemia. It occurs when a mother's immune system produces antibodies against her baby's Rh-positive blood cells.
The disease develops when Rh-negative mothers carry Rh-positive babies. During pregnancy or delivery, fetal blood cells may enter the mother's circulation, triggering production of anti-Rh antibodies. These antibodies can cross back into the fetus during subsequent pregnancies, destroying red blood cells and causing anemia.
| Type | Severity | Timing |
|---|---|---|
| Mild | Minimal anemia | First pregnancy |
| Moderate | Moderate anemia | Second pregnancy |
| Severe | Hydrops fetalis | Third pregnancy or later |
Rhesus haemolytic disease is prevented through Rh immunoglobulin injections given to Rh-negative mothers during pregnancy and after delivery. Treatment for affected fetuses includes intrauterine transfusions and early delivery.
Another misconception is that only first-time mothers are at risk. While first pregnancies rarely cause issues, subsequent pregnancies increase the risk due to the mother's sensitized immune response.
I witnessed a case where a mother, unaware of her Rh-negative status, gave birth to a severely anemic baby. Early detection and treatment were important, highlighting the importance of prenatal screening and Rh immunoglobulin injections.
Rhesus haemolytic disease remains a significant concern for Rh-negative mothers carrying Rh-positive babies. Understanding the condition, its prevention, and treatment options is important for ensuring healthy outcomes for both mother and child.